• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

委内瑞拉疟疾患者的CYP2D6基因型与伯氨喹治疗

CYP2D6 Genotype and Primaquine Treatment in Patients with Malaria, Venezuela.

作者信息

Pacheco César, Hernández-Acosta Adán, Pulido Narviz, Ceballos Yvanna, Saavedra Daniel, Gómez Cruz, Moreno Nancy, Herrera Flor

出版信息

Emerg Infect Dis. 2025 Sep;31(9):1807-1810. doi: 10.3201/eid3109.250316.

DOI:10.3201/eid3109.250316
PMID:40867022
Abstract

We determined CYP2D64 and CYP2D6 genotypes and metabolizer phenotypes in 96 patients with suspected malaria in Venezuela and found intermediate or poor metabolizer phenotypes in ≈25% of cases. Nine of 44 malaria patients had Plasmodium vivax recurrence. Public health authorities should evaluate the benefits of increasing total doses of primaquine for treatment.

摘要

我们测定了委内瑞拉96例疑似疟疾患者的CYP2D64和CYP2D6基因型及代谢表型，发现约25%的病例存在中间或慢代谢表型。44例疟疾患者中有9例出现间日疟复发。公共卫生当局应评估增加伯氨喹总剂量用于治疗的益处。

相似文献

1
CYP2D6 Genotype and Primaquine Treatment in Patients with Malaria, Venezuela.委内瑞拉疟疾患者的CYP2D6基因型与伯氨喹治疗
Emerg Infect Dis. 2025 Sep;31(9):1807-1810. doi: 10.3201/eid3109.250316.
2
Polymorphisms of the CYP2D6 gene and its relationship with Plasmodium vivax relapses after chloroquine-primaquine treatment in Turbo, Colombia.哥伦比亚图尔博地区CYP2D6基因多态性及其与氯喹-伯氨喹治疗后间日疟原虫复发的关系。
Diagn Microbiol Infect Dis. 2025 Nov;113(3):117013. doi: 10.1016/j.diagmicrobio.2025.117013. Epub 2025 Jul 16.
3
Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function.在 CYP2D6 功能受损的患者中，正确使用伯氨喹治疗后出现数例间日疟原虫复发。
Malar J. 2020 Jul 17;19(1):259. doi: 10.1186/s12936-020-03326-1.
4
Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria.细胞色素 P450 2D6 活性基因型和表型受损与磷酸萘酚喹治疗潜伏性间日疟原虫疟疾的疗效相关性研究。
JAMA Netw Open. 2018 Aug 3;1(4):e181449. doi: 10.1001/jamanetworkopen.2018.1449.
5
Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report.从西非感染的间日疟原虫多次复发与 CYP2D6 代谢不良变异体相关：病例报告。
BMC Infect Dis. 2019 Aug 9;19(1):704. doi: 10.1186/s12879-019-4357-9.
6
CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study.CYP2D6 活性与巴西亚马逊地区间日疟复发风险：一项前瞻性队列研究。
Malar J. 2018 Feb 1;17(1):57. doi: 10.1186/s12936-017-2139-7.
7
Novel Insights into Plasmodium vivax Therapeutic Failure: CYP2D6 Activity and Time of Exposure to Malaria Modulate the Risk of Recurrence.新型疟原虫治疗失败见解：CYP2D6 活性和疟疾暴露时间调节复发风险。
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.02056-19.
8
Four Times of Relapse of Plasmodium vivax Malaria Despite Primaquine Treatment in a Patient with Impaired Cytochrome P450 2D6 Function.一名细胞色素P450 2D6功能受损患者在接受伯氨喹治疗后间日疟四次复发
Korean J Parasitol. 2022 Feb;60(1):39-43. doi: 10.3347/kjp.2022.60.1.39. Epub 2022 Feb 23.
9
14 days of high-dose versus low-dose primaquine treatment in patients with Plasmodium vivax infection in Cambodia: a randomised, single-centre, open-label efficacy study.柬埔寨间日疟原虫感染患者接受14天高剂量与低剂量伯氨喹治疗的随机、单中心、开放标签疗效研究
Lancet Infect Dis. 2025 Aug;25(8):884-895. doi: 10.1016/S1473-3099(25)00033-7. Epub 2025 Mar 17.
10
Association between CYP2D6 phenotype and recurrence of Plasmodium vivax infection in south Korean patients.CYP2D6 表型与韩国患者间日疟原虫感染复发的关系。
Malar J. 2022 Oct 10;21(1):289. doi: 10.1186/s12936-022-04311-6.

本文引用的文献

1
Global perspectives on associations with primaquine metabolism and radical cure.关于伯氨喹代谢与根治关系的全球观点。
Front Pharmacol. 2022 Nov 15;13:752314. doi: 10.3389/fphar.2022.752314. eCollection 2022.
2
Higher-Dose Primaquine to Prevent Relapse of Malaria.高剂量磷酸萘酚喹预防疟疾复发。
N Engl J Med. 2022 Mar 31;386(13):1244-1253. doi: 10.1056/NEJMoa2104226.
3
2D6 Allele Frequency in Five Malaria Vivax Endemic Areas From Brazilian Amazon Region.巴西亚马逊地区五个间日疟流行区的2D6等位基因频率
Front Pharmacol. 2021 Jul 23;12:542342. doi: 10.3389/fphar.2021.542342. eCollection 2021.
4
Genetic Variation and Its Implication for Vivax Malaria Treatment in Madagascar.马达加斯加间日疟原虫疟疾治疗中的基因变异及其意义
Front Pharmacol. 2021 Apr 20;12:654054. doi: 10.3389/fphar.2021.654054. eCollection 2021.
5
PharmVar GeneFocus: CYP2D6.PharmVar 基因焦点：CYP2D6。
Clin Pharmacol Ther. 2020 Jan;107(1):154-170. doi: 10.1002/cpt.1643. Epub 2019 Dec 9.
6
Ten Years' Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics.CYP2D6活性评分十年经验：关于未来研究以改善精准治疗临床预测的展望
J Pers Med. 2018 Apr 17;8(2):15. doi: 10.3390/jpm8020015.
7
[Allelic variants of the CYP2D6: *4, *6 and *10 in a sample of resident from the Aragua state, Venezuela].[委内瑞拉阿拉瓜州居民样本中CYP2D6的等位基因变体：*4、*6和*10]
Rev Peru Med Exp Salud Publica. 2015 Oct;32(4):746-51.
8
CYP2D6 gene variants in urban/admixed and Amerindian populations of Venezuela: pharmacogenetics and anthropological implications.委内瑞拉城市/混合人群和美洲印第安人群中的CYP2D6基因变异：药物遗传学和人类学意义
Ann Hum Biol. 2012 Mar;39(2):137-42. doi: 10.3109/03014460.2012.656703.